drugset / Trial / NCT05265910

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis

NCT05265910

Phase 4 Completed 58 enrolled Andover Research Eye Institute
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a single-center, randomized, double-masked, parallel study. In this clinical study, the efficacy comparison between Pataday® Once Daily Relief Extra Strength and Claritin® Tablets 24-Hour will be made using the Ora-CAC model, a validated clinical model accepted by regulatory agents for assessing the efficacy of products on the signs and symptoms of allergic conjunctivitis.

Timeline

Start
2021-12-14
Primary completion
2022-04-23
Completion
2022-04-23

Drugs

EvaluationDrugModalityDoseRoute
Comparator Loratadine Small molecule 10 mg Oral
Comparator Olopatadine Other / unclassified 0.7 % Other
Comparator Tears Naturale Unknown

Indications